Who Will Emerge Victorious In US Showdown On Stelara?
Seven Approved Ustekinumab Biosimilars Set To Launch In Early 2025
US biosimilar competition to Stelara is waiting in the wings from the very start of 2025. But with seven ustekinumab rivals already approved by the FDA and set to launch, how will things shake out in such a crowded market? Generics Bulletin looks at the contenders.
